

Pre - PA Allowance

None

Prior-Approval Requirements

Diagnoses

Patient must have **ONE** of the following:

1. X-linked hypophosphatemia (XLH) (also called X-linked dominant hypophosphatemic rickets, X-linked vitamin D-resistant rickets)
 - a. 6 months of age or older
 - b. Confirmed diagnosis by genetic testing of PHEX (phosphate regulating gene with homology to endopeptidases located on the X chromosome) mutation in the patient
2. FGF23-related hypophosphatemia in tumor-induced osteomalacia (TIO)
 - a. 2 years of age or older
 - b. Associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized

AND ALL of the following:

1. Patient will discontinue any oral phosphate or active vitamin D analog supplementation at least one week prior to starting therapy with Crysvida
2. Prescriber agrees to measure serum phosphorous throughout therapy and withhold medication when serum phosphorus is above the reference range for age
3. Administered by a healthcare provider

AND NONE of the following:

1. Fasting serum phosphorus is within or above the normal range for age
2. eGFR < 30 mL/min/1.73 m²

Prior - Approval Limits

Duration 12 months

Prior – Approval *Renewal* Requirements

Diagnoses

Patient must have **ONE** of the following:



1. X-linked hypophosphatemia (XLH) (also called X-linked dominant hypophosphatemic rickets, X-linked vitamin D-resistant rickets)
 - a. 6 months of age or older
2. FGF23-related hypophosphatemia in tumor-induced osteomalacia (TIO)
 - a. 2 years of age or older

AND ALL of the following:

1. Prescriber agrees to measure serum phosphorous throughout therapy and withhold medication when serum phosphorus is above the reference range for age
2. Administered by a healthcare provider

AND NONE of the following:

1. eGFR < 30 mL/min/1.73 m²

Prior - Approval *Renewal* Limits

Same as above